Latest Articlesddd

Amgen’s Underrated Great News. Array Pharma’s Smart Move

March 21, 2017 0

AMGEN Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against …

Nektar: Killing Pain While Fighting Addiction. Stock is Up 28 Percent

March 20, 2017 0

Nektar Therapeutics (NKTR) announced positive results from the SUMMIT-07 Phase 3 efficacy study of its painkiller …

OncoCyte’s Liquid Biopsy Test Has Positive News

March 15, 2017 0

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests …

Prohost Letter #406

March 13, 2017 0

Prohost Letter #406 A Special Prohost Issue SYNOPSIS REASONS FOR THE FOLLOWING PROHOST PICKS RALLIES VERTEX …

Prohost Letter #405

March 10, 2017 0

Prohost Letter #405 Synthetic Biology (3) We have already decided upon becoming shareholders the day synthetic …

Ionis Drug Volanesorsen’s Reward Outweighs the Mitigated Risk

March 8, 2017 0

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals (IONS), announced positive results from the pivotal …

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

March 6, 2017 0

A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg …

Why Would a Specific Rheumatoid Arthritis Drug Treat Aggressive Cancers? Read Also: Other Important News

March 3, 2017 0

An approved rheumatoid arthritis drug developed and sold by Sanofi could become a new treatment for …

Kite Pharma’s CAR-T Therapy Passed the Test with High Grades

March 2, 2017 0

We keep reiterating that CAR-T cancer immunotherapy was created to stay. More frequent updates about the …

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

February 27, 2017 0

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of …

Incyte: A Thoughtful Research and Collaboration Agreement with Abramson Cancer Center

February 24, 2017 0

Incyte Announces a Multi-year Research Collaboration with the Abramson Cancer Center at the University of Pennsylvania. …

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

February 23, 2017 0

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise …

Agenus: Why Canceling Prophage Trial Should Not be Concerning

February 22, 2017 0

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore …

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

February 21, 2017 0

Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other …

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

February 17, 2017 0

About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

February 14, 2017 0

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

February 14, 2017 0

Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …

Interpreting Portola Pharmaceuticals’ News

February 9, 2017 0

The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …

Gilead Sciences: A Case Study

February 9, 2017 0

Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …

Prohost Letter #404 Part 2

February 6, 2017 0

Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …